Thanks, Mike. I'd like to start, by thanking our Petco partners, for their relentless efforts in 2023. While we experienced a challenging year, they continued to do everything they can, to deliver the very best, for pets and pet parents day in and day out. Turning to numbers, for the quarter, net revenue was $1.7 billion, an increase of 6% year-over-year, which includes an extra week in the fourth quarter. For the full year, net revenue was $6.3 billion, up 4% year-over-year, inclusive of the extra week, which contributed approximately $120 million in revenue in Q4 and for the full year. In Q4, comparable sales on a like-for-like fiscal basis, were down 1%, driven primarily by the absence of discretionary recovery, and lapping a more inflationary environment. While we saw early gains in revenue, from the aggregate impact of our assortment actions, they were relatively small in magnitude for the quarter. For the full year, comp sales were up 2%. Unless otherwise specified, the results I'll discuss, are on an as-reported basis, including the extra week in Q4. In the fourth quarter, our services team delivered 17% revenue growth, driven by ongoing strength in our vet hospitals, mobile clinics, and grooming services. In merchandise, consumables was up 9% year-over-year, reflecting the impact of lapping prior year inflation, coupled with the pricing actions, we took in the third quarter. Our discretionary supplies, and companion animals businesses, experienced continued softness down 1% year-over-year. Moving down to P&L, Q4 gross profit was $606 million, down from $627 million in the prior year. Gross margin for the quarter, was 36.2%, a decline of 350 basis points, driven by our investment in bringing value brands, into our consumables assortment, and ongoing discretionary headwinds. In Q4, we also took a $21 million inventory write-down charge, as a direct one-time response, to our assortment actions that were taken in connection with our operational reset, with approximately 60% of the charge, related to lower velocity supply SKUs, and 40%, related to consumable SKUs that, will no longer be part of the assortment. This charge, was a necessary step, to optimize our SKU footprint - and our reset is now completed, and we believe we are in a good place, with inventory. Ex-inventory reset gross margins would have been 37.5%. In terms of the new brands, although it is still early days, we are pleased to say that we are seeing positive momentum, in both transactions and basket, leading to a small, but positive net impact on revenue, from our assortment and pricing changes. This has translated to positive customer net ads in the fourth quarter, suggesting early momentum from our reset. In Q4, SG&A as a percentage of revenue, increased from 34.8% to 36.2% year-over-year, as a result of ongoing investments made in store labor, as well as increased depreciation. Q4 adjusted EBITDA, was $105.3 million, down 33%, with an adjusted EBITDA margin rate of 6.3%, down 370 basis points, year-over-year. Q4 adjusted EPS was $0.02, compared to $0.20 per share, in the prior year. Turning to the balance sheet, our liquidity remains strong, with $572 million inclusive of $125 million in cash and cash equivalents, and $447 million of availability on our revolving credit facility. As a reminder, we also maintain callers, on roughly two-thirds of our debt, which have helped mitigate the impact of rising rates this year. Our Q4 CapEx of $49 million is down 26%, year-over-year. I'll now turn, to our 2024 outlook. Given the change in leadership, we are not providing full year guidance, at this time. Instead, we are providing revenue, adjusted EBITDA, and adjusted EPS guidance, for fiscal Q1 only. For the first quarter, should current demand conditions persist, we would expect revenue, of approximately $1.5 billion, adjusted EBITDA of approximately $70 million, and adjusted EPS of approximately negative $0.06. For 2024, which as a reminder, will be a 52-week year, the environment remains uncertain, and as a result, we are taking a prudent approach, to our plans for the year. From a full year perspective, we expect net interest expense, of approximately $145 million, inclusive of the estimated impacts of our hedges, against the forward rate curve, and $272 million weighted average, fully diluted shares. Approximately $140 million of capital expenditures, including the build-out of approximately five to 10 vet locations. In the meantime, our mobile clinics business, continues to perform ahead of our expectations, and we're confident that the demand there, will help support vet economics. To provide some additional color regarding assumptions for the full year, we are currently not expecting a substantive change, to the underlying demand environment, including discretionary. With respect to profitability, there are a number of actions that, are being contemplated, as part of the leadership transition. We will communicate as those plans are finalized. We do expect stabilization of profitability, as the year progresses. Although we are seeing early traction from implementing our assortment and pricing actions, we believe the scaled revenue, and profit benefits, will take time to phase in, increasing throughout the year. We remain on track to achieve $40 million in cost benefits, in year one from the cost opportunities we identified, as part of the planned 150 million in run rate savings, by year end 2025. That said, the cost benefits will be partially offset, by additional investments into store labor, to ensure that we deliver a differentiated, hands-on customer experience in our stores, as well as mitigation against gross margin. On capital allocation, we remain focused on our balance sheet, as we navigate this environment, leading to a deceleration in our pace of that build out, and a balanced approach, between investments and cash flow. To close, our focal points this year, are disciplined execution, operating in a more efficient manner with a focus on expenses, stabilizing margins, and cash. Thank you for your time. And with that, we'll be happy to take your questions.